comparemela.com

Latest Breaking News On - International medical approval - Page 1 : comparemela.com

Global clinical development on Dengue antiviral candidate will start, Hyundai Bioscience strives to win emergency use authorization

/PRNewswire/ South Korea s biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry.

South koreaUnited statesPuerto ricoSoult ukpyolsiRepublic ofSang giCholla buktoJoobin jungHyundai bioscienceSouth americaSoutheast asiaBioscience united statesGlobal marketing managerHealth care amp hospitalsInfection controlMedical pharmaceuticals

Daewoong Pharmaceutical s Bersiporocin Receives Orphan Drug Designation in Europe to Treat Idiopathic Pulmonary Fibrosis

/PRNewswire/ Daewoong Pharmaceutical s Bersiporocin (DWN12088) has been recognized as a significant advancement in treating idiopathic pulmonary fibrosis.

South koreaSoult ukpyolsiEuropean molecular biology organizationClinical developmentEuropean medicines agencyKorea drug development fundOrphan drug designationClinical development supportDaewoong pharmaceuticalDaewoong pharmaceutical coHealth care amp hospitalsMedical pharmaceuticalsInternational medical approval

European Medicines Agency (EMA) Grants Orphan Drug Designation (ODD) to GC Biopharma s Treatment for Sanfilippo Syndrome (Type A)

/PRNewswire/ GC Biopharma Corp. (006280.KS) announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation (ODD) to its.

South koreaYelin junRachel kimSohee kimEuropean medicines agencyGc biopharma corpPrnewswire gc biopharma corpGreen cross corporationOrphan drug designationEnzyme replacement therapySanfilippo syndromeRare pediatric diseaseNovel pharmaGc biopharmaHealth care amp hospitalsMedical pharmaceuticals

Anixa Biosciences Announces Japanese Patent on Ovarian Cancer Vaccine Technology

/PRNewswire/ Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a clinical-stage biotechnology company focused on the treatment and.

Amit kumarSuparna mazumderAnixa biosciencesVincent tuohyJustin johnsonMike catelaniAnixa biosciences incNational cancer instituteDepartment of inflammationMoffitt cancer centerCleveland clinic lerner research instituteJapan patent officeInnovative breast cancer researchCleveland clinicCancer vaccinesOvarian cancer vaccines

Mission Therapeutics granted MHRA Clinical Trial Authorisation (CTA) for MTX325 for the treatment of Parkinson s Disease

/PRNewswire/ Mission Therapeutics ("Mission" or the "Company"), a clinical-stage biotech developing first-in-class therapeutics targeting mitophagy, today.

United kingdomAnker lundemoseSuhail nurbhaiPaul thompsonPrnewswire mission therapeuticsCambridge universityIp groupMission therapeuticsRoche venture fundRegulatory agencyNature communicationsHarvard universityNature reviews drug discoveryChief executive officerChief scientific officerChief medical officer

vimarsana © 2020. All Rights Reserved.